Key Drivers
- High Margins
- Strong Cash Flow
- Intangible Overhang
AIAI Summary
CRMD should now be viewed less as a speculative biotech and more as a cash-generating commercial name whose valuation hinges on whether DefenCath can sustain margins through the H2 2026 reimbursement reset, with REZZAYO providing longer-term upside only if execution stays on track.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High Margins
- •Strong Cash Flow
- •Intangible Overhang
CRMD remains fundamentally strong with high margins, robust cash generation, and improved liquidity, but profitability softened versus FY2025 and leverage/intangibles remain the main risks.
Price Behavior
Key Price Behavior Insights:
- •Higher lows
- •Resistance stall
- •Range-bound action
Over the last month, CRMD is modestly higher but still range-bound, with support around $7.40–$7.50 and resistance near $7.90–$8.05, so a clean breakout is needed to improve the near-term setup.
Briefly hit $8.05 on 2026-05-06 before slipping to $7.55 on 2026-05-15
Sentiment & News
Key News Insights:
- •Q1 beat
- •Guidance raise
- •Pipeline progress
CorMedix posted a strong Q1 with earnings, revenue, and guidance all beating expectations on DefenCath/Melinta momentum, while positive REZZAYO Phase III data adds to the bullish outlook.
The results and clinical update are likely to support a positive near-term view on CRMD, reinforcing growth visibility and investor confidence
Similar Companies in Healthcare
Other companies in the same sector with AI ratings